Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif

Journal of Virology

Volumn 74, Issue 22, 2000, Pages 10447-10457

  Leutenegger, C M ^a   Boretti, F S ^a   Mislin, C N ^a   Flynn, J N ^a   Schroff, M ^a   Habel, A ^a   Junghans, C ^a   Koenig Merediz, S A ^a   Sigrist, B ^a   Aubert, A ^a   Pedersen, N C ^a   Wittig, B ^a   Lutz, H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; GOLD; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 16; MIDGE VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION FUNCTION; CPG ISLAND; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FELINE IMMUNODEFICIENCY VIRUS; GENE GUN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS INFECTION; SEROCONVERSION; VIREMIA; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; CATS; CPG ISLANDS; CYTOKINES; DNA, VIRAL; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; GENETIC VECTORS; GLYCOPROTEINS; IMMUNODEFICIENCY VIRUS, FELINE; INTERLEUKIN-12; INTERLEUKIN-16; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; PROVIRUSES; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA; VIRAL VACCINES;

EID: 0033755678     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.22.10447-10457.2000     Document Type: Article

References (74)

1. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major
2. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression
3. HIV suppression by interleukin-16
4. The effects of DNA containing CpG motif on dendritic cells
5. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons
6. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group
7. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 1 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir
8. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression
9. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
10. Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors
11. Mucosally transmitted feline immunodeficiency virus induces a CD8+ antiviral response that correlates with reduction of cell-associated virus
12. Serological diagnosis of feline immunodeficiency virus infection using recombinant transmembrane glycoprotein
13. Interleukin-12: A bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency
14. + T lymphocytes suppresses FIV replication
15. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro
16. DNA-based immunization by in vivo transfection of dendritic cells
17. DNA vaccination using expression vectors carrying FIV structural genes induces immune response against feline immunodeficiency virus
18. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
19. An experimental study of primary feline immunodeficiency virus infection in cats and a historical comparison to acute simian and human immunodeficiency virus diseases
20. Nucleotide and predicted peptide sequence of feline interleukin-12 (IL-12)
21. Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide
22. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain
23. Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination
24. Evaluation of feline immunodeficiency virus and feline leukemia virus transmembrane peptides for serological diagnosis
25. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis
26. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine
27. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques
28. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia
29. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
30. CpG DNA as a Th1 trigger
31. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells
32. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells
33. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: Hematology, clinical chemistry, and lymphocyte subsets
34. Feline immunodeficiency virus vaccination: Characterization of the immune correlates of protection
35. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies
36. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: Implications for the augmentation of Th1 responses
37. Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis
38. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators
39. A role for IL-16 in the cross-talk between dendritic cells and T cells
40. Conservation of structure and function between human and murine IL-16
41. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis
42. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
43. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory
44. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
45. CpG motifs in bacterial DNA trigger direct B-cell activation
46. Construction of chimeric simian and human immunodeficiency viruses that produce interleukin 12
47. Molecular cloning and expression of rhesus macaque and sooty mangabey interleukin 16: Biologic activity and effect on simian immunodeficiency virus infection and/or replication
48. Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system
49. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins
50. Molecular cloning and expression of feline interleukin-16
51. Molecular characterization of feline interleukin 16: Chemotactic activity and effect on feline immunodeficiency virus infection and/or replication
52. Quantitative real-time PCR for the measurement of feline cytokine mRNA
53. Elevated interleukin-10-to-interleukin-12 ratio in feline immunodeficiency virus-infected cats predicts loss of type 1 immunity to Toxoplasma gondii
54. Adjuvant modulation of immune responses to tuberculosis subunit vaccines
55. Specificity assessment of feline T-lymphotropic lentivirus serology
56. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual
57. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals
58. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12
59. Identification of conserved and variable regions in the envelope glycoprotein sequences of two feline immunodeficiency viruses isolated in Zurich, Switzerland
60. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site
61. Decreases CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants
62. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
63. Expansion of CD8alpha+beta-cells in cats infected with feline immunodeficiency virus
64. Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats
65. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge
66. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer
67. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
68. Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines
69. DNA vaccines
70. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: Constraints on immune escape associated with targeting a sequence essential for viral replication
71. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
72. IL-12 gene expression in human skin-derived CD1a+ dendritic lymph cells
73. Processing, secretion, and anti-HIV-1 activity of IL-16 with or without a signal peptide in CD4+ T cells
74. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression